GIT Pharmacology

Peptic Ulcer Disease and GIT Pharmacology

Classification of Drugs

  • Proton Pump Inhibitors (PPIs)

    • Omeprazole

    • Esomeprazole

    • Pantoprazole

    • Lansoprazole

  • H2 Receptor Antagonists

    • Ranitidine

    • Famotidine

    • Cimetidine

  • Antacids

    • Magnesium hydroxide

    • Aluminum hydroxide

    • Calcium carbonate

  • PG Analogue

    • Misoprostol

  • Mucosal Protective Agents

    • Sucralfate

  • Antibiotics

    • Bismuth subsalicylate

    • Amoxicillin

    • Clarithromycin

    • Metronidazole

Omeprazole

  • Mechanism of Action (MOA)

    • Irreversibly inhibits the H+/K+ ATPase enzyme located on the parietal cells of the stomach.

    • This inhibition blocks the final step in gastric acid secretion, leading to a significant reduction in gastric acid production.

    • Since it irreversibly inhibits the proton pump, acid secretion is reduced until new proton pumps are synthesized by parietal cells.

  • Pharmacological Actions

    1. Inhibition of gastric acid secretion.

    2. Increased gastric pH.

    3. Healing of ulcers.

    4. Eradication of H. pylori (as an adjunct therapy).

Therapeutic Uses of Omeprazole

  1. Peptic Ulcer Disease (PUD)

  2. Gastroesophageal Reflux Disease (GERD)

  3. Zollinger-Ellison Syndrome

  4. H. pylori infection

  5. NSAID-induced ulcers.

Adverse Effects of Omeprazole

  • Gastrointestinal (GIT): Nausea, vomiting, diarrhea, constipation, abdominal pain.

  • Nutritional Deficiencies:

    • Vitamin B12 deficiency

    • Hypomagnesemia

    • Osteoporotic-related fractures.

  • Clostridium difficile infection.

  • Acute interstitial nephritis.

  • Rebound acid hypersecretion.

Contraindications

  1. Hypersensitivity to omeprazole.

  2. Liver disease (hepatic impairment).

  3. Osteoporosis.

  4. Caution in pregnancy.

  5. Iron malabsorption.

Drug Interactions

  • Clopidogrel: Omeprazole can reduce the effectiveness of clopidogrel, an antiplatelet drug, by inhibiting the enzyme CYP2C19.

  • Warfarin: Omeprazole can increase the effects of warfarin, leading to an increased risk of bleeding.

  • Diazepam: Omeprazole can inhibit the metabolism of diazepam.

  • Methotrexate: High doses of methotrexate may interact with PPIs, increasing the risk of methotrexate toxicity.

  • Digoxin: Omeprazole increases the absorption of digoxin, leading to digoxin toxicity.

Ranitidine

  • Mechanism of Action (MOA)

    • Ranitidine selectively blocks H2 receptors on parietal cells of the stomach, reducing gastric acid secretion in response to histamine, gastrin, and acetylcholine (Ach).

    • This inhibition lowers both basal and stimulated gastric acid production, decreasing the acidity of the stomach.

  • Therapeutic Uses

    1. Peptic Ulcer Disease (PUD)

    2. Gastroesophageal Reflux Disease (GERD)

    3. Zollinger-Ellison Syndrome

    4. Prevention of stress ulcers.

    5. Heartburn & dyspepsia.

Adverse Effects of Ranitidine

  • CNS: Headache, dizziness, confusion.

  • GIT: Diarrhea, constipation, abdominal discomfort.

  • Cardiovascular (CVS): Bradycardia or hypotension.

  • Blood: Thrombocytopenia.

  • Endocrine: Gynecomastia & impotence.

  • Infections: Increased risk of infections, such as C. difficile.

Contraindications

  1. Hypersensitivity to ranitidine.

  2. Renal or hepatic impairment.

  3. Caution in elderly patients due to risk of CNS effects.

Anti-H. pylori Regimens

  • Triple Therapy

    • Proton Pump Inhibitor (PPI): Omeprazole or Pantoprazole.

    • Clarithromycin: 500mg twice daily.

    • Amoxicillin: 1g twice daily or Metronidazole: 500mg twice daily.

    • Duration: 10–14 days.

  • Quadruple Therapy (for resistant cases or areas with high clarithromycin resistance)

    • Proton Pump Inhibitor (PPI).

    • Bismuth subsalicylate: 300mg once daily.

    • Tetracycline: 500mg four times daily.

    • Metronidazole: 500mg three times daily.

    • Duration: 10–14 days.

Pantoprazole

  • Mechanism of Action (MOA)

    • Similar to omeprazole, pantoprazole irreversibly binds to and inhibits the H+/K+ ATPase (proton pump) in the parietal cells of the stomach, thus reducing the final step in gastric acid production.

  • Therapeutic Uses

    1. Peptic Ulcer Disease (PUD)

    2. Gastroesophageal Reflux Disease (GERD)

    3. Zollinger-Ellison Syndrome

    4. H. pylori eradication regimens.

Adverse Effects of Pantoprazole

  • Headache, nausea, diarrhea, constipation.

  • Hypomagnesemia.

  • Bone fractures.

  • Rebound acid hypersecretion.

  • Increased infections (e.g., C. difficile).

Contraindications

  1. Hypersensitivity to pantoprazole.

  2. Liver disease.

Antacids

  • Antacids are substances that neutralize stomach acid, providing rapid relief from acid-related symptoms like heartburn and indigestion.

  • Examples:

    1. Magnesium hydroxide: Neutralizes acid and has a laxative effect.

    2. Aluminum hydroxide: Neutralizes acid and may cause constipation.

    3. Calcium carbonate: Provides quick relief but may cause rebound acid production.

    4. Sodium bicarbonate: Fast acting, but not preferred due to risk of metabolic alkalosis and sodium retention.

Mechanism of Action (MOA) of Antacids

  • Antacids react with HCl in the stomach to form water and salt, thus neutralizing gastric acid and increasing the pH of the stomach.

Therapeutic Uses of Antacids

  • Symptomatic relief of heartburn, indigestion, GERD, and peptic ulcers.

Adverse Effects of Antacids

  • Diarrhea

  • Constipation

  • Hypercalcemia.

  • Metabolic alkalosis.

Colloidal Bismuth Subcitrate

  • A mucosal protective agent used in the treatment of peptic ulcer disease and part of quadruple therapy for H. pylori eradication.

Mechanism of Action (MOA)

  • Forms a protective barrier over the ulcer base by binding to proteins in the ulcer site, shielding it from acid and pepsin.

  • Stimulates the secretion of mucus and bicarbonate, providing additional protection.

  • Exhibits antibacterial action against H. pylori.

Therapeutic Uses

  1. Peptic Ulcer Disease (PUD)

  2. Chronic gastritis.

  3. Part of quadruple therapy for H. pylori eradication.

Adverse Effects

  1. Blackening of the tongue and stools.

  2. Nausea, vomiting, and constipation.

  3. Bismuth toxicity.

Contraindications

  1. Renal failure.

  2. Hypersensitivity reactions.

Metoclopramide

  • A prokinetic agent and antiemetic commonly used in the management of various disorders and to prevent nausea and vomiting.

Mechanism of Action (MOA)

  1. Dopamine D2 Receptor Antagonism: Blocks D2 dopamine receptors in the chemoreceptor trigger zone (CTZ), preventing vomiting initiation.

  2. Serotonin (5-HT4) Agonist: Stimulates the release of Ach in the GI tract, increasing motility and accelerating gastric emptying.

  3. Serotonin (5-HT3) Antagonist: At high doses, provides additional antiemetic effects.

  4. Increased Lower Esophageal Sphincter (LES) Tone: Helps prevent reflux.

Therapeutic Uses

  1. Gastroesophageal Reflux Disease (GERD)

  2. Nausea and vomiting.

  3. Gastroparesis

  4. Hiccups

  5. Prevention of aspiration.

Adverse Effects

  • Postoperative nausea and vomiting, chemotherapy-induced nausea.

  • Extrapyramidal Symptoms: Dystonia, akathisia, dyskinesia, parkinsonism.

  • Neuroleptic Malignant Syndrome.

  • Sedation.

  • Hyperprolactinemia.

Contraindications

  1. Hypersensitivity reactions.

  2. Depression, hypotension, bradycardia, diarrhea.

  3. Epilepsy.

  4. Pheochromocytoma.

Ondansetron

  • A selective serotonin (5-HT3) receptor antagonist primarily used to prevent nausea and vomiting.

Mechanism of Action (MOA)

  • Blocks serotonin 5-HT3 receptors in the central nervous system, particularly in the gastrointestinal tract.

  • Prevents the initiation of the vomiting reflex triggered by serotonin release from the enterochromaffin cells in the small intestine during nausea and vomiting.

Pharmacological Actions

  1. Anti-emetic action → prevention of nausea and vomiting induced by chemotherapy or surgery.

Therapeutic Uses

  1. Chemotherapy-induced nausea and vomiting.

  2. Radiation therapy.

  3. Postoperative nausea and vomiting.

Adverse Effects

  1. Headache.

  2. Constipation.

  3. Fatigue and dizziness.

  4. Diarrhea.

  5. QT prolongation.

  6. Serotonin syndrome.

  7. Hypersensitivity reactions.

Domperidone

  • A dopamine antagonist with antiemetic and prokinetic properties.

Mechanism of Action (MOA)

  • Blocks dopamine D2 receptors in the CTZ and in the GI tract, leading to:

    1. Antiemetic Effect: Prevents nausea and vomiting by inhibiting dopamine receptors in the CTZ.

    2. Prokinetic Effect: Enhances GI motility by increasing Ach release, improving gastric emptying and esophageal peristalsis.

Therapeutic Uses

  1. Nausea and vomiting.

  2. GERD.

  3. Gastroparesis.

  4. Dyspepsia.

  5. Lactation induction (off-label).

Adverse Effects

  1. Dry mouth and abdominal cramps.

  2. Diarrhea.

  3. Headache.

  4. Galactorrhea and amenorrhea.

  5. Gynecomastia.

  6. Cardiac arrhythmias.

  7. Sudden cardiac death (rare).

Role of Neuroleptics in Nausea and Vomiting Management

  • Neuroleptics (antipsychotics) act as effective antiemetics by blocking dopamine D2 receptors in the CTZ.

  • Mechanism of Action (MOA)

    1. Dopamine Antagonism (D2 receptors): Blocks dopamine receptors, preventing nausea and vomiting signals.

    2. Some neuroleptics also block serotonin, histamine (H1), and muscarinic cholinergic receptors, further increasing their antiemetic effects.

  • Examples:

    • Chlorpromazine

    • Prochlorperazine

    • Haloperidol

    • Droperidol

    • Olanzapine

Therapeutic Uses

  1. Chemotherapy-induced nausea and vomiting.

  2. Postoperative nausea and vomiting.

  3. Radiation therapy-induced nausea.

  4. Drug-induced vomiting.

  5. Palliative care.

Adverse Effects

  1. Extrapyramidal symptoms: Dystonia, akathisia, parkinsonism.

  2. Sedation.

  3. Anticholinergic effects.

  4. Orthostatic hypotension.

  5. QT prolongation.

  6. Metabolic effects: Dry mouth, constipation, blurred vision, urinary retention, weight gain, hyperglycemia, lipid abnormalities.

Antimotility and Antisecretory Agents

  • Classes of medications used to manage diarrhea by reducing stool frequency and improving consistency.

Antimotility Agents

  • Slow intestinal motility, allowing more time for water and electrolyte absorption, which helps decrease stool frequency and improve consistency.

    • Examples:

    • Loperamide: Slows gut movement, increases absorption of fluids and electrolytes.

    • Diphenoxylate with atropine: Reduces intestinal motility.

Antisecretory Agents

  • Reduce the secretion of fluids and electrolytes into the intestinal lumen.

    • Examples:

    • Racecadotril: An enkephalinase inhibitor that reduces intestinal fluid secretion.

    • Bismuth subsalicylate: Reduces intestinal secretions; has anti-inflammatory and antibacterial effects.

Probiotics

  • Not directly antisecretory, but restore the natural balance of gut flora, which may reduce the secretion of harmful bacterial toxins and fluids in infected bacteria.

Osmotic Laxatives
Mechanism of Action (MOA)

  • Work by increasing the amount of water in the bowel through osmosis, leading to softer stools and increased bulk, promoting bowel movement.

  • Therapeutic Uses

    1. Constipation

    2. Preparation for colonoscopy.

Common Osmotic Laxatives

  1. Polyethylene glycol (Miralax)

  2. Lactulose

  3. Magnesium hydroxide

  4. Magnesium citrate

  5. Sodium phosphate.

Adverse Effects of Osmotic Laxatives

  1. Dehydration.

  2. Electrolyte imbalance.

  3. Abdominal discomfort.

  4. Diarrhea.

  5. Renal impairment.

  6. Nausea and vomiting.

Liquid Paraffin

  • Works as a lubricant laxative by coating stools and intestinal walls to soften and facilitate passage.

Therapeutic Uses

  1. Constipation treatment.

  2. Fecal impaction.

Adverse Effects

  1. Aspiration pneumonia.

  2. Anal leakage.

  3. Malabsorption of fat-soluble vitamins (A, D, E, K).

  4. Bloating and abdominal discomfort.

  5. Lipid granulomas.

Bisacodyl

  • A stimulant laxative used to treat constipation and prepare for certain medical procedures.

Mechanism of Action (MOA)

  • Directly stimulates nerve endings in the colonic mucosa, increasing peristaltic movement and promoting water and electrolyte secretion.

Therapeutic Uses

  1. Constipation.

  2. Bowel preparation.

Adverse Effects

  1. Abdominal cramping.

  2. Diarrhea.

  3. Electrolyte imbalance.

  4. Laxative dependence.

  5. Nausea and vomiting.

Stool Softeners (Emollient Laxatives)

  • Examples: Docusate sodium, docusate calcium, docusate potassium.

Mechanism of Action (MOA)

  • Increase water and fat content in stool through surfactants, reducing surface tension and allowing a mixture of water and fats for easier passage.

Therapeutic Uses

  1. Constipation.

  2. Prevent straining.

Adverse Effects

  1. Diarrhea.

  2. Abdominal cramping.

  3. Electrolyte imbalance.

  4. Dependence.

Comparison: Cimetidine Vs. Ranitidine

Feature

Cimetidine

Ranitidine

Potency

Less potent

5 times more potent

Duration of Action

Shorter duration of action

Longer duration of action

Central Nervous System

More CNS penetration leading to CNS effects (confusion, headache, delirium)

Less CNS penetration, fewer CNS side effects

Adverse Effects

Gynecomastia, reduced sperm count, impotence, menstrual irregularities, galactorrhea in females

Fewer adverse effects compared to cimetidine

Drug Interactions

Inhibits microsomal enzymes; may lead to increased plasma levels of drugs metabolized by these enzymes causing toxicity

Fewer drug interactions

Sucralfate

Mechanism of Action (MOA)

  • Forms a protective barrier over the ulcer and damaged mucosal tissue in the stomach and duodenum by interacting with HCl to create a viscous gel that adheres to the ulcer site.

  • Protects the ulcer from further irritation by stomach acid and bile salts and promotes healing; also stimulates mucus and bicarbonate production for enhanced GI protection.

Therapeutic Uses

  1. Peptic Ulcer Disease (PUD)

  2. Gastroesophageal Reflux Disease (GERD)

  3. Prevention of stress ulcers.

Adverse Effects

  1. Constipation

  2. Dry mouth

  3. Nausea or vomiting.

Drugs Used in GERD

  1. Proton Pump Inhibitors (PPIs) → Omeprazole, Esomeprazole, Lansoprazole

  2. H2 Blockers → Ranitidine, Famotidine, Cimetidine

  3. Antacids → Aluminum hydroxide, Magnesium hydroxide, Calcium carbonate.

  4. Prokinetics → Metoclopramide, Domperidone

  5. Foaming Agents → Sucralfate, Alginates.

  6. Baclofen.

Drugs Used in Dissolution of Gallstones

  1. Ursodeoxycholic Acid (UDCA): Reduces cholesterol saturation in bile and increases bile acid solubility, used to dissolve gallstones.

  2. Chenodeoxycholic Acid (CDCA): Reduces hepatic secretion of cholesterol and enhances bile acid synthesis, can be used for the dissolution of cholesterol gallstones.

Reasons for Combining Antacids Before Administration

  1. Symptomatic relief.

  2. Mucosal protection: Rapid relief of heartburn and dyspepsia by neutralizing gastric acid, protecting gastric and duodenal mucosa by reducing acidity.

  3. Minimize adverse effects.

  4. Adjunct therapy with other medications like PPIs or H2 blockers to enhance overall effectiveness in managing acid-related disorders.

Prokinetics

  1. Metoclopramide: Used for nausea, vomiting & gastroparesis.

  2. Domperidone: Used for nausea, vomiting & helps with gastric emptying.

  3. Cisapride: Used for GERD & gastroparesis.

  4. Erythromycin: An antibiotic that also promotes gastric emptying.

  5. Prucalopride: Used for chronic constipation.

  6. Tegaserod: Used for IBS with constipation.

Digestants and Their Therapeutic Uses

  1. Pancrelipase: Treats pancreatic insufficiency (e.g., in cystic fibrosis).

  2. Pepsin: Used along with HCl in gastric achylia due to atrophic gastritis, gastric carcinoma, pernicious anemia, etc.

  3. Papain: An enzyme used in digestive supplements.

  4. Hydrochloric Acid: Used in achlorhydria.

  5. Diastase & Therasage: Used for various digestive issues.

  6. Pancreatin: A mixture of digestive enzymes.

Antiemetic Agents

  1. Ondansetron: 5-HT3 receptor antagonist used for chemotherapy-induced nausea & vomiting.

  2. Metoclopramide: Prokinetic agent that acts as an antiemetic.

  3. Promethazine: Antihistamine with antiemetic properties.

  4. Granisetron: 5-HT3 receptor antagonist for nausea & vomiting.

  5. Dexamethasone: Corticosteroid used for nausea associated with chemotherapy.

  6. Aprepitant: Neurokinin-1 antagonist for chemotherapy-induced nausea.

Classification of Laxatives

  • Bulk-forming Laxatives: Absorb water and expand in the intestine, promoting peristalsis (e.g., Psyllium, Methyl cellulose).

  • Osmotic Laxatives: Draw water into the intestine, softening stool and increasing bowel movement frequency (e.g., Lactulose, Sorbitol, Polyethylene glycol).

  • Stimulant Laxatives: Stimulate the intestinal wall to enhance peristalsis (e.g., Bisacodyl, Senna).

  • Emollient Laxatives: Soften stool by increasing water penetration (e.g., Docusate sodium, Docusate calcium).

  • Saline Laxatives: Increase osmotic pressure in the intestines, drawing water into the lumen (e.g., Magnesium hydroxide, Sodium sulfate).

Classification of Antidiarrheal Agents

  1. Opioid Derivatives: Decrease bowel motility and prolong transit time (e.g., Loperamide, Diphenoxylate).

  2. Adsorbents: Absorb excess fluid and stabilize the gut (e.g., Pectin, Kaolin).

  3. Antisecretory Agents: Reduce secretions and may have antimicrobial properties (e.g., Bismuth subsalicylate).

  4. Probiotics: Restore gut flora and improve gut function (e.g., Lactobacillus, Saccharomyces boulardii).

Role of Probiotics in Diarrhea

  • Probiotics are beneficial microorganisms that help restore the balance of gut flora disrupted during diarrhea.

  1. Enhance recovery time from acute infectious diarrhea.

  2. Prevent antibiotic-associated diarrhea: Help maintain healthy gut flora during antibiotic usage.

  3. Improve overall gut health: Potentially reduce the risk of recurrent diarrhea.

Role of Zinc in Pediatric Diarrhea

  • Zinc plays a vital role in the management of pediatric diarrhea by:

  1. Reducing the duration and severity of diarrhea.

  2. Supporting immune function: Zinc supplementation can shorten the duration of diarrhea and reduce severity.

  3. Promoting gut health: Essential for maintaining intestinal mucosal integrity and reducing the risk of future episodes.

Oral Rehydration Solution (ORS)

Composition

  • Basic ingredients:

    • Glucose

    • Sodium chloride

    • Potassium chloride

    • Sodium bicarbonate

  • A standard ORS solution contains:

    • Sodium: 75 mEq/L

    • Glucose: 75g/L

    • Potassium: 20 mEq/L

    • Bicarbonate/Citrate: 10 mEq/L

Preparation

  • Dissolve the specified amount of ORS powder in a specific volume of clean water (typically 1 liter) and ensure the solution is mixed well and used within 24 hours.

Therapeutic Uses

  1. Rehydration: Treat dehydration caused by diarrhea, vomiting, and other fluid losses.

  2. Electrolyte replenishment.

Pharmacotherapy for Inflammatory Bowel Disease (IBD)

  1. Aminosalicylates: For induction and maintenance of remission in mild to moderate IBD (e.g., Mesalamine, Sulfasalazine).

  2. Corticosteroids: Short-term management for flare-ups and moderate to severe IBD (e.g., Prednisone, Budesonide).

  3. Immunomodulators: Long-term management and maintenance of remission (e.g., Azathioprine, Mercaptopurine, Methotrexate).

  4. Antibiotics: For specific cases (e.g., Metronidazole, Ciprofloxacin).

  5. Biologics: Target specific pathways in the inflammatory process, used for moderate to severe cases (e.g., Infliximab, Adalimumab).

Non-Diarrheal Uses of ORS

  1. Hydration in Vomiting

  2. Heat Stroke / Exhaustion

  3. Post-operative Recovery

Classification of Drugs
Proton Pump Inhibitors (PPIs)

  • Omeprazole
      - One of the first PPIs introduced into the market; provides long-lasting reduction in gastric acid production.

  • Esomeprazole
      - An isomer of omeprazole with potentially improved pharmacokinetics, increasing bioavailability.

  • Pantoprazole
      - Less potent than other PPIs but effective for conditions requiring rapid gastric acid suppression.

  • Lansoprazole
      - Exhibits quick onset of action and a longer duration of effect, making it suitable for immediate symptom relief.

H2 Receptor Antagonists

  • Ranitidine
      - Formerly one of the most commonly used H2 blockers, it works effectively to decrease gastric acid secretion.

  • Famotidine
      - Has a higher potency compared to ranitidine and may offer a longer duration of action.

  • Cimetidine
      - The oldest H2 blocker, known for potential drug interactions due to its effect on cytochrome P450 enzymes.

Antacids

  • Magnesium hydroxide
      - Rapidly neutralizes gastric acid and often used in combination with other antacids to alleviate side effects.

  • Aluminum hydroxide
      - Has a slower onset but provides prolonged acid neutralization; it can also cause constipation.

  • Calcium carbonate
      - Immediately neutralizes stomach acid, but can lead to rebound increases in acid production in some patients.

PG Analogue

  • Misoprostol
      - Used for preventing NSAID-induced ulcers by promoting mucus and bicarbonate secretion and enhancing mucosal defense.

Mucosal Protective Agents

  • Sucralfate
      - A sucrose-sulfate complex that adheres to ulcer sites, providing a protective barrier, and must be taken on an empty stomach for optimal effect.

Antibiotics

  • Bismuth subsalicylate
      - Known for its antimicrobial properties against H. pylori, it also has absorptive and protective effects on the gastric lining.

  • Amoxicillin
      - Frequently used in combination therapies for H. pylori eradication due to its effectiveness and low resistance rates.

  • Clarithromycin
      - A key component of triple therapy regimens for H. pylori treatment, known for its efficacy against gram-positive bacteria.

  • Metronidazole
      - Effective against anaerobic bacteria and parasites, used particularly when resistance is identified in H. pylori strains.

Omeprazole

  • Mechanism of Action (MOA)
      - Irreversibly inhibits the H+/K+ ATPase enzyme located on the parietal cells of the stomach, leading to prolonged reduction in gastric acid secretion until new proton pumps are synthesized.

  • Pharmacological Actions
      1. Effective inhibition of gastric acid secretion.
      2. Raises gastric pH significantly, aiding in ulcer healing.
      3. Promotes mucosal healing through decreased acidity.
      4. Assists in the eradication of H. pylori when used as an adjunct in therapy.

Therapeutic Uses of Omeprazole

  1. Treating Peptic Ulcer Disease (PUD) effectively by reducing acid load.

  2. Managing Gastroesophageal Reflux Disease (GERD) by alleviating symptoms of reflux.

  3. Treatment of Zollinger-Ellison Syndrome, a condition characterized by gastric acid overproduction.

  4. Contributing to the eradication of H. pylori infections as part of combination therapy.

  5. Providing protection against NSAID-induced ulcers in patients at risk.

Adverse Effects of Omeprazole

  • Gastrointestinal (GIT): Commonly presents as nausea, vomiting, diarrhea, constipation, and abdominal discomfort.

  • Nutritional Deficiencies:
      - Notably Vitamin B12 deficiency can occur due to changes in gastric pH affecting absorption.
      - Hypomagnesemia may lead to electrolyte imbalances and muscle spasms.
      - Increases the risk of osteoporotic-related fractures due to impaired calcium absorption.

  • Risks of Clostridium difficile infection due to altered gut flora.

  • Incidence of acute interstitial nephritis reported in some patients.

  • Rebound acid hypersecretion upon abrupt cessation after long-term use.

Contraindications

  1. Known hypersensitivity to omeprazole.

  2. Pre-existing liver disease or hepatic impairment.

  3. History of osteoporosis or risk factors.

  4. Caution advised in pregnancy, especially in first trimester.

  5. Be mindful of iron malabsorption situations.

Drug Interactions

  • Clopidogrel: Can significantly reduce the effectiveness due to CYP2C19 inhibition.

  • Warfarin: Potential for increased anticoagulant effect, requiring monitoring.

  • Diazepam: Omeprazole may inhibit its metabolism, leading to enhanced sedative effects.

  • Methotrexate: In high doses, interacts increasing the risk of toxicity.

  • Digoxin: Enhances absorption, increasing the risk of digoxin toxicity.

Ranitidine

  • Mechanism of Action (MOA)
      - Selectively blocks H2 receptors on parietal cells in the stomach, reducing overall gastric acid secretion in response to various stimuli including histamine, gastrin, and Ach.

  • Therapeutic Uses
      1. Effective in treating Peptic Ulcer Disease (PUD).
      2. Managing GERD symptoms effectively.
      3. Treating Zollinger-Ellison Syndrome for acid control.
      4. Preventive measures against stress ulcers in at-risk populations.
      5. Alleviating heartburn and dyspepsia issues in patients.

Adverse Effects of Ranitidine

  • CNS: Headaches, potential dizziness, and confusion in some elderly patients.

  • GIT: Incidences of diarrhea or constipation, along with abdominal discomfort.

  • Cardiovascular (CVS): Rare occurrences of bradycardia or hypotension.

  • Blood: Risk of thrombocytopenia in some patients.

  • Endocrine: Potential for gynecomastia or impotence with chronic use.

  • Infections: Increased susceptibility to infections like C. difficile due to reduced acidity.

Contraindications

  1. Previous hypersensitivity episodes related to ranitidine.

  2. Renal or hepatic impairment.

  3. Increased caution in elderly patients due to risk of CNS effects.

Anti-H. pylori Regimens

  • Triple Therapy
      - Proton Pump Inhibitor (PPI): Omeprazole or Pantoprazole.
      - Clarithromycin: Dosage of 500mg twice daily.
      - Amoxicillin: 1g twice daily or alternatively, Metronidazole at 500mg twice daily.
      - Duration should be maintained for 10–14 days.

  • Quadruple Therapy
      - Proton Pump Inhibitor (PPI) as the core component.
      - Bismuth subsalicylate: 300mg dosed once daily.
      - Tetracycline: Given at 500mg four times daily.
      - Metronidazole: 500mg three times daily.
      - Duration also centered around 10–14 days.

Pantoprazole

  • Mechanism of Action (MOA)
      - Inhibits the H+/K+ ATPase enzyme irreversibly in parietal cells, mirroring the action of omeprazole and achieving similar therapeutic effects.

  • Therapeutic Uses
      1. Often indicated for Peptic Ulcer Disease (PUD).
      2. Efficacious in GERD management.
      3. Plays a role in handling Zollinger-Ellison Syndrome.
      4. Indispensable in H. pylori eradication protocols.

Adverse Effects of Pantoprazole

  • Can lead to common symptoms such as headache, nausea, and gastrointestinal disturbances like diarrhea and constipation.

  • May result in hypomagnesemia or contribute to bone fracture risks.

  • Reports of rebound acid hypersecretion are noted upon discontinuation.

  • Increased susceptibility to infections like C. difficile in prolonged use cases.

Contraindications

  1. Documented hypersensitivity to pantoprazole.

  2. Patients with liver disease or impairment noted for caution.

Antacids

  • Work primarily by neutralizing gastric acid, providing symptomatic relief from conditions including heartburn and indigestion.

  • Examples:
      1. Magnesium hydroxide: Provides rapid acid-neutralizing action and has a mild laxative effect.
      2. Aluminum hydroxide: Effective in neutralizing gastric acid while potentially causing constipation.
      3. Calcium carbonate: Offers quick relief and can lead to rebound acid production if used excessively.
      4. Sodium bicarbonate: Provides fast relief but is avoided in high-risk individuals due to the risk of metabolic alkalosis.

Mechanism of Action (MOA) of Antacids

  • React with gastric hydrochloric acid to neutralize it, increasing gastric pH and relieving symptoms associated with acid-related conditions.

Therapeutic Uses of Antacids

  • Effective for symptomatic relief from heartburn, indigestion, GERD, and peptic ulcers through immediate acid-neutralizing action.

Adverse Effects of Antacids

  • Potential gastrointestinal effects including diarrhea or constipation, hypercalcemia, and metabolic alkalosis with inappropriate usage.

Colloidal Bismuth Subcitrate

  • Acts as a mucosal protective agent crucial for the management of peptic ulcer disease and adjunctive treatment in H. pylori eradication.

Mechanism of Action (MOA)

  • Forms a protective gel over ulcerated mucosal surfaces, attaches to ulcer sites, and encourages secretion of protective mucus and bicarbonate.

Therapeutic Uses

  1. Treating Peptic Ulcer Disease (PUD).

  2. Addressing chronic gastritis symptoms.

  3. Serving as a component in quadruple therapy for H. pylori eradication.

Adverse Effects

  1. Can lead to blackening of the tongue and stools due to bismuth content.

  2. Experience of nausea, vomiting, or constipation.

  3. Risk of bismuth toxicity with excess use.

Contraindications

  1. Patients with renal failure.

  2. Individuals with documented hypersensitivity to any of the components.

Metoclopramide

  • A versatile prokinetic agent and antiemetic utilized across various clinical scenarios to manage nausea and vomiting effectively.

Mechanism of Action (MOA)

  1. Dopamine D2 Receptor Antagonism: Blocks central receptors to inhibit the vomiting reflex.

  2. Serotonin (5-HT4) Agonism: Enhances acetylcholine release in the GI tract, stimulating motility and facilitating gastric emptying.

  3. Serotonin (5-HT3) Antagonism: Provides additional antiemetic effects at elevated doses.

  4. Increased Lower Esophageal Sphincter (LES) Tone: Mitigates reflux occurrences.

Therapeutic Uses

  1. Managing GERD symptoms effectively.

  2. Addressing nausea and vomiting in various settings.

  3. Useful in gastroparesis for enhancing gastric motility.

  4. Assisting with hiccup management and preventing aspiration.

Adverse Effects

  • Potential to cause postoperative nausea and chemotherapy-induced nausea.

  • Extrapyramidal Symptoms: Risk exists for disorders such as dystonia and parkinsonism.

  • May lead to sedation and elevated prolactin levels, causing galactorrhea and amenorrhea.

Contraindications

  1. Known hypersensitivity reactions.

  2. History of depression, hypotension, and bradycardia.

  3. Patients with epilepsy or pheochromocytoma deserve special caution.

Neurohumoral Regulation of Appetite

  • Appetite regulation involves complex interactions between neural and hormonal signals. It primarily operates through the central nervous system and peripheral endocrine systems.

  • Key Hormones:
      - Ghrelin: Produced by the stomach, it stimulates appetite and promotes food intake; levels increase before meals and decrease after.
      - Leptin: Secreted by adipose (fat) tissues, it signals satiety to the hypothalamus, suppressing appetite.
      - Peptide YY (PYY): Released by the intestine after eating, it reduces appetite and inhibits gastric motility.
      - Cholecystokinin (CCK): Secreted by the small intestine in response to food intake, it stimulates digestion and promotes satiety.

Neurohumoral Regulation of Gastrointestinal Motility (Peristalsis)

  • Peristalsis refers to the coordinated, rhythmic contractions of the intestinal muscles that propel food through the digestive tract.

  • Neurohumoral Factors:
      - Autonomic Nervous System:
        - Parasympathetic Activation: Increases peristalsis through the release of acetylcholine, enhancing gut motility.
        - Sympathetic Activation: Decreases motility and inhibits peristalsis through norepinephrine.
      - Enteric Nervous System (ENS):
        - Often referred to as the "second brain," it communicates autonomously to regulate gut motility through neural circuits, including myenteric plexus, which coordinates smooth muscle contractions.
      - Hormonal Influences:
        - Gastrin: Stimulates gastric motility and acid secretion.
        - Motilin: Triggers the migrating motor complex (MMC) in fasting states.

Role of Secretory Glands and Their Enzymes in Food Digestion

  • Secretory glands in the gastrointestinal tract produce various enzymes and substances essential for digestion:
      - Salivary Glands: Secrete saliva containing enzymes such as amylase which begins the digestion of carbohydrates.
      - Gastric Glands: Produce gastric juice, including hydrochloric acid (HCl) and pepsinogen:
        - HCl: Lowers pH, activates pepsinogen to pepsin, aiding protein digestion.
        - Pepsin: Breaks down proteins into peptides.
      - Pancreas: Exocrine function secretes digestive enzymes into the small intestine:
        - Amylase: Continues carbohydrate digestion.
        - Lipase: Breaks down fats into fatty acids and glycerol.
        - Proteases (e.g., trypsin and chymotrypsin): Further digest proteins into smaller peptides.
      - Liver: Produces bile aids in the emulsification and digestion of fats in the small intestine.

Neurohumoral Regulation of Gastric Secretion

  • Gastric secretion is regulated through neural and hormonal mechanisms:
      - Cephalic Phase: Triggered by the sight or smell of food; involves the brain signaling the stomach to prepare for digestion:
        - Increases secretion of gastrin and gastric acid.
      - Gastric Phase: Initiated when food is present in the stomach:
        - Local Reflexes: Stretch receptors initiate vagal reflexes increasing gastric juice production.
        - Hormonal Response: Increased release of gastrin in response to protein presence in the stomach, which enhances acid secretion.
      - Intestinal Phase: Begins with food entering the small intestine:
        - Enterogastric Reflex: Hormonal feedback mechanism reduces gastric secretion as food enters the small intestine to prevent overloading.
        - Secretin: Released when acidic chyme enters the duodenum, inhibits gastrin and gastric acid secretion, promoting bicarbonate secretion from the pancreas to neutralize the acid.

  • These neurohumoral mechanisms together ensure effective regulation of appetite, motility, digestion, and secretion in the gastrointestinal tract, facilitating efficient digestion and nutrient absorption.